This meta-analysis demonstrated that GLP1-RA treatment improved hepatic steatosis, liver function, lipid, glucose, inflammatory and insulin sensitivity markers, which indicates a synergistic treatment approach for patients with T2DM and NAFLD. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.